RxDoctor Payments Data

Nataliya Kukhar, MD

Family Medicine · Moline, ILNPI 1780868604

Payments from drug & device makers

$868in general payments, 2019–2025

Across 25 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$341
  • Lilly USA, LLC$159
  • Novo Nordisk$124
  • Medtronic$115
  • Dexcom, Inc.$68
  • Sanofi Pasteur Inc.$24
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$868 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$126,469
Medicare patients
195
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$171,614
JanuviaSitagliptin Phosphate65$82,622
Xeljanz XrTofacitinib Citrate11$63,229
EliquisApixaban58$50,625
MounjaroTirzepatide19$29,908
Spiriva RespimatTiotropium Bromide35$23,698
XareltoRivaroxaban18$22,069
Spiriva HandihalerTiotropium Bromide23$21,620
TradjentaLinagliptin41$18,745
SymbicortBudesonide/Formoterol Fumarate45$14,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,729
LinzessLinaclotide16$14,032
Incruse ElliptaUmeclidinium Bromide32$13,876
JardianceEmpagliflozin11$12,544
FarxigaDapagliflozin Propanediol11$9,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$124$171,614152 claims
Boehringer IngelheimSpiriva Respimat, Tradjenta, Jardiance$19$54,98787 claims
Lilly USA, LLCMounjaro$159$29,90819 claims
AbbVieLinzess$341$14,03216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →